Publish in OALib Journal
APC: Only $99
In the year 2000 lung cancer was operated in 349 patients in Norway, in 2010 the number was 461. In the first period fatal surgical hemorrhage occurred in eight patients, in four of them peroperatively. Postoperative hemorrhage occurred in four patients in the year 2000 and in two in 2010. Ten patients died intra- or postoperatively in the two periods which is a mortality rate within 30 days after surgery of 4.3% in the first and 1.1% in the second period. Pneumonectomy was performed in 34 patients in 2000 and eight in 2010, respectively. Altogether 19 patients died within six months after surgery without having experienced surgical complications. Pneumonectomy should not be performed in elderly and debilitated persons.
To explore the therapeutic effects and therapeutic mechanisms of Conditional
Replication Adenovirus(CRAd) in combination with cisplatin on lung cancer
cells. Methods: Using MTS / PMS assay, in
vitro cell inhibition assay was performed to detect the cell viability of
two lung cancer cell lines, NCI-H292 and NCI-H661. PCR was employed to detect
the Coxsackie receptor(CAR) expression of cancer cells. The in vivo anti-tumor effect of CRAd and
cisplatin was evaluated using a subcutaneous mouse model. Results: The CRAd
with cisplatin is superior to the use of cisplatin or CRAd viruse alone on the
suppression of lung cancer cell growth. The mechanism of inhibition is
associated with the increased CAR expression. Conclusion: The application of
CRAd in combination with cisplatin could play a better therapeutic effect on
lung cancer cell growth inhibition.
Objective: The aim of the study was to
improve the therapeutic effect for lung cancer using a synergetic strategy of
adenovirus-based gene therapy combined with chemotherapy. Methods: A conditional replication adenovirus(CRAd) was employed
to treat the A549 lung cancer cells and cisplatin-resisted A549(A549-DDP) cells.
In vitro MTS / PMS assay were used to evaluate
the cell viability. PCR were used to detect expression of Coxsackie receptor (CAR)
and Multidrug resistance(MDR) gene. The in
vivo anti-tumor effect of CRAd and cisplatin was evaluated using a
subcutaneous mouse model. Results: The CRAd sensitizes A549 cancer cells to
cisplatin. The mechanism of enhanced cell growth inhibition is associated with the
increased CAR and MDR expression. Conclusion: Our approach is better than the
conventional gene therapy and chemotherapy strategy.
In 2008, 1.6 million new cases of lung cancer were diagnosed worldwide,
representing 13% of all cancer cases for the year, and in 2010, 19% of cancer
deaths were attributed to lung cancer. Though lung cancer frequently
metastasizes to the adrenal glands, bone, brain, liver, and other lung, it
infrequently metastasizes to the heart. Here, we report a case of lung cancer
metastatic to the mitral valve.
Lung cancer is a lethal
malignancy, however, no serum marker is routinely
recommended till now. Prospectively two groups of patients included: Group I: Patients with advanced lung
cancer. Group II: patients with
benign lung disease as control. Serum Tissue Polypeptide Antigen (TPA) levels
were measured by ELISA technique before the first line chemotherapy. The TPA cutoff taken was 1800 pg./ml. End points were comparison of high TPA
in cases and controls and correlation between high TPA and disease progression
(PD), progression free survival (PFS) and overall survival (OS). 30 patients
with advanced lung cancer (16 non-small and 14 small cell lung cancer) and 15
patients with benign lung disease were included and followed up during the
period from October 2008 to October 2011 with median follow-up of 1.5 years.
High TPA was found in 50% of lung cancer cases compared to 26% in controls (p = 0.014).
Lung cancer is one of the most
aggressive and lethal form of cancers. Patients with far advanced lung cancer
are treated by chemotherapy with or without radiotherapy. However, median
survival of these patients is less than 6 months. To increase survival and
quality of life for these patients, various forms of complementary treatments
have been tried in clinical practices, and oncothermia is supposed to be one of
the promising candidates. From May 2008 to November 2013, 4 patients with far
advanced lung adenocarcinoma (stages IIIB and IV) were treated with oncothermia
in addition to conventional chemotherapy at Gangnam Severance Hospital and
Bundang CHA Hospital. All these patients have survived for more than 2 years.
Background: To those patients with advanced lung cancer, the ultimate objective is to improve the quality of life, and lung function is an important factor affecting quality of life. We detect lung function of patients with lung cancer and study the correlation between lung function and the patients’ survival time, to provide reference for evaluation of disease progression and prognosis. Methods: Lung function was detected on 59 cases of lung cancer and 63 normal controls. The relationship between lung function indexes and survival time was analyzed. Results: There was significant difference in ventilation function and diffusing capacity between lung cancer group and control group. Vital capacity (VC), Forced expiratory volume in one second (FEV1), Forced vital capacity (FVC), peak expiratory flow (PEF), peak expiratory flow% (PEF%), Maximal ventilatory volume (MVV) were positively correlated to survival time in patients with advanced lung cancer (r = 0.28522064, 0.28053851, 0.28289252, 0.26908133, 0.26335034, 0.28409036, P < 0.05), residual volume/total lung capacity was negatively correlated to survival time (r = ?0.30760097, P < 0.05). Conclusions: The lung function decrease in the patients with lung cancer. Vital capacity (VC), Forced expiratory volume in one second (FEV1), Forced vital capacity (FVC), peak expiratory flow (PEF), peak expiratory flow% (PEF%), Maximal ventilatory volume (MVV), and residual volume/total lung capacity are correlated to survival time in patients with advanced lung cancer. The lung function indexes are important marker of prognosis of patients with lung